Consensus Immunovant, Inc.

Equities

IMVT

US45258J1025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
27.75 ^USD	-3.65%		-2.01%	-34.13%

Apr. 20	Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	MT
Apr. 20	Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Immunovant, Inc.

Price target over the last 5 years

History of analyst recommendation changes

76fc.Y-6cHfPQhlwUTgAR3j4JhF_6HwHzVhEtdvA2HzVlDfE.DILmWpGhyiZkJU8lqlhjvGyrTGiVLFZeA7VMeGECY8AF2LFch5nQEHgpYw~573139ea708174f966ce8e580b92682f

Analyst Recommendations on Immunovant, Inc.

Immunovant Insider Sold Shares Worth $990,269, According to a Recent SEC Filing	Apr. 19	MT
Immunovant Insider Sold Shares Worth $293,923, According to a Recent SEC Filing	Apr. 19	MT
Oppenheimer Initiates Coverage on Immunovant With Outperform Rating, $50 Price Target	Mar. 28	MT
Goldman Sachs Starts Coverage on Immunovant With Buy Rating, $50 Price Target	Mar. 13	MT
JPMorgan Starts Coverage on Immunovant With Overweight Rating, $51 Price Target	Feb. 20	MT
Wolfe Research Starts Immunovant With Outperform Rating, $55 Price Target	Feb. 15	MT
HC Wainwright Adjusts Price Target on Immunovant to $51 From $47, Keeps Buy Rating	Dec. 21	MT
Immunovant's Batoclimab for Graves' Disease Produces Meaningful Response Rates in Study; Shares Jump After Hours	Dec. 20	MT
Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates	Dec. 20	CI
Deutsche Bank Initiates Coverage on Immunovant With Buy Rating, $50 Price Target	Dec. 12	MT
UBS Raises Immunovant Price Target to $56 From $55, Maintains Buy Rating	Dec. 01	MT
Truist Adjusts Price Target on Immunovant to $48 From $30, Maintains Buy Rating	Nov. 15	MT
Piper Sandler Adjusts Immunovant's Price Target to $57 From $28, Maintains Overweight Rating	23-10-24	MT
HC Wainwright Adjusts Immunovant Price Target to $47 From $29, Maintains Buy Rating	23-10-24	MT
UBS Upgrades Immunovant to Buy From Neutral, Adjusts Price Target to $55 From $18	23-10-13	MT
Wall St. pounded as investors grapple with higher rates	23-09-26	RE
Citigroup Raises Immunovant Price Target to $50 From $33, Maintains Buy Rating	23-09-26	MT
Wall St slides as rate concerns keep Treasury yields near 16-year peak	23-09-26	RE
Raymond James Upgrades Immunovant to Outperform From Market Perform, $40 Price Target	23-09-26	MT
Wells Fargo Adjusts Immunovant Price Target to $48 From $33, Maintains Overweight Rating	23-09-26	MT
Guggenheim Adjusts Immunovant Price Target to $48 From $32, Maintains Buy Rating	23-09-26	MT
Wall St poised for weak open as rate worries keep Treasury yields elevated	23-09-26	RE
Citigroup Adjusts Price Target on Immunovant to $33 From $28, Maintains Buy Rating	23-08-11	MT
Wells Fargo Raises Immunovant's Price Target to $33 From $27, Maintains Overweight Rating	23-07-24	MT
Stifel Nicolaus Adjusts Immunovant Price Target to $34 From $28, Maintains Buy Rating	23-07-18	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

27.75 USD

Average target price

50.43 USD

Spread / Average Target

+81.72%

High Price Target

56 USD

Spread / Highest target

+101.80%

Low Price Target

40 USD

Spread / Lowest Target

+44.14%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immunovant, Inc.

Oppenheimer
Goldman Sachs
JPMorgan Chase
Wolfe Research
HC Wainwright
Deutsche Bank Securities
UBS
Truist Securities
Piper Sandler
Wells Fargo Securities
Citigroup
Guggenheim
Raymond James
Stifel Nicolaus
BofA Securities
Chardan Research
Cantor Fitzgerald
SVB Securities LLC
Chardan
Baird
SVB Leerink
Credit Suisse

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar